MY206715A - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
MY206715A
MY206715A MYPI2022001387A MYPI2022001387A MY206715A MY 206715 A MY206715 A MY 206715A MY PI2022001387 A MYPI2022001387 A MY PI2022001387A MY PI2022001387 A MYPI2022001387 A MY PI2022001387A MY 206715 A MY206715 A MY 206715A
Authority
MY
Malaysia
Prior art keywords
sulfate
nasal polyps
pharmaceutical composition
chondroitin
reducing agent
Prior art date
Application number
MYPI2022001387A
Other languages
English (en)
Inventor
Shigeharu Fujieda
Tetsuji Takabayashi
Kanako Yoshida
Hideki Watanabe
Koki FUJIKAWA
Original Assignee
Univ Fukui
Maruho Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Fukui, Maruho Kk filed Critical Univ Fukui
Publication of MY206715A publication Critical patent/MY206715A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733Fructosans, e.g. inulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MYPI2022001387A 2019-09-20 2020-09-18 Pharmaceutical composition MY206715A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019170955 2019-09-20
PCT/JP2020/035438 WO2021054440A1 (ja) 2019-09-20 2020-09-18 医薬組成物

Publications (1)

Publication Number Publication Date
MY206715A true MY206715A (en) 2025-01-03

Family

ID=74883058

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2022001387A MY206715A (en) 2019-09-20 2020-09-18 Pharmaceutical composition

Country Status (10)

Country Link
US (1) US20220347093A1 (https=)
EP (1) EP4032535A4 (https=)
JP (1) JP7313019B2 (https=)
CN (3) CN114650828B (https=)
AU (1) AU2020349263B2 (https=)
BR (1) BR112022003464A2 (https=)
CA (1) CA3154360C (https=)
MY (1) MY206715A (https=)
PH (1) PH12022550661A1 (https=)
WO (1) WO2021054440A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3144752A1 (fr) * 2023-01-10 2024-07-12 Song Huang Utilisation de polysulfate de pentosane pour le traitement de la toux seche

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3497209B2 (ja) 1993-08-24 2004-02-16 生化学工業株式会社 硫酸化糖の脱硫酸化方法
JP3512277B2 (ja) 1995-10-05 2004-03-29 有限会社ジーオーメディカルサービス 鼻茸治療・予防剤
JPH10203988A (ja) 1997-01-27 1998-08-04 Meiji Milk Prod Co Ltd 鼻茸および鼻粘膜の浮腫性病変の治療剤
JPH11335288A (ja) * 1998-05-20 1999-12-07 Maruho Co Ltd アレルギー性疾患の予防または治療薬
WO2000069917A1 (fr) * 1999-05-18 2000-11-23 Maruho Kabushikikaisha Compositions medicinales destinees a inhiber le systeme kallikreine-kinine ou la phospholipase a¿2?
EP1922076A4 (en) 2005-08-03 2013-01-23 Morria Biopharmaceuticals USE OF LIPID CONJUGATES IN CYSTIC FIBROSIS AND ITS APPLICATIONS
US20140005115A1 (en) * 2005-11-17 2014-01-02 Yissum Research Development Company Lipid conjugates in the treatment of bronchitis
US8859524B2 (en) * 2005-11-17 2014-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of chronic rhinosinusitis
CA2790682C (en) 2010-03-03 2020-11-24 Neocutis Sa Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
CN111437387B (zh) 2013-06-21 2024-10-01 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗鼻息肉症的方法
JP6637587B2 (ja) * 2015-08-04 2020-01-29 ズートツッカー アーゲー 副鼻腔炎に対するイヌリンの予防的使用

Also Published As

Publication number Publication date
EP4032535A1 (en) 2022-07-27
CN114650828A (zh) 2022-06-21
CA3154360C (en) 2024-01-23
WO2021054440A1 (ja) 2021-03-25
AU2020349263B2 (en) 2023-08-17
CA3154360A1 (en) 2021-03-25
BR112022003464A2 (pt) 2022-05-24
CN118976045A (zh) 2024-11-19
CN118416094A (zh) 2024-08-02
JPWO2021054440A1 (https=) 2021-03-25
US20220347093A1 (en) 2022-11-03
EP4032535A4 (en) 2023-10-25
JP7313019B2 (ja) 2023-07-24
AU2020349263A1 (en) 2022-04-14
PH12022550661A1 (en) 2023-03-27
CN114650828B (zh) 2024-08-06

Similar Documents

Publication Publication Date Title
Jiang et al. Chitosan as a biomaterial: structure, properties, and applications in tissue engineering and drug delivery
RU2020119390A (ru) Применение каннабиноидов при лечении приступов, связанных с синдромом леннокса-гасто
PH12021550104A1 (en) High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
MY198582A (en) Pentosan polysulfate, pharmaceutical composition, and anticoagulant
CA2286552A1 (en) Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine
MX386086B (es) Composicion de cannabis
EA201070299A1 (ru) Противовирусная композиция, содержащая сульфатированный полисахарид
WO2014152796A3 (en) Biocompatible and bioabsorbable derivatized chitosan compositions
NZ603479A (en) Chitosan composition
BR112018002466A2 (pt) proteção de conteúdo aplicado em hardware para unidades de processamento gráfico
MY206715A (en) Pharmaceutical composition
HUE063875T2 (hu) Eljárások E. coli O-antigén poliszacharidok biokonjugátumainak elõállítására, ezek készítményei és felhasználásuk módszerei
EP4591939A3 (en) Formulations of sodium thiosulfate
MX2021007061A (es) Composición farmacéutica que comprende 4-(2-fluoro-4-(3-(2- fenilacetil)tioureido)fenoxi)-7-metoxi-n-metilquinolina-6-carboxa mida e hidroxipropil-b-ciclodextrina.
PH12019550138A1 (en) Pharmaceutical combinations for treating cancer
BR112017026104A2 (pt) novos usos de derivados de aril-quinolina como inibidores de mimetismo vasculogênico
WO2021074649A3 (en) Methods of promoting scfa production by gut microbiota
PH12019500511A1 (en) Detergent compositions comprising ultra-low molecular weight polysaccharides
ZA202311374B (en) Improvements in or related to organic compounds
WO2019125330A3 (en) Nasal decongestant compositions comprising dexpanthenol and sodium hyaluronate
BR102016028651A2 (pt) polissacarídeos modificados.
PH12020550775A1 (en) Pentosan polysulfate and medicine containing pentosan polysulfate
WO2018136779A3 (en) OXALOBACTER FORMIGENES(Of)-DERIVED FACTORS FOR THE TREATMENT OF TREATMENT/PREVENTION OF EXCESS OXALATE LEVELS
JP2002145779A5 (https=)